Wechselwirkungen · Drovelis
Drovelis 3 mg/14.2 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-146475 · Präparat HOS-099526
Concomitant use with the HCV medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir, with or without ribavirin, may increase the risk of ALT elevations in women using ethinylestradiol containing medicinal products such as CHCs (see section 4.4). Women using medicinal products containing oestrogens other than ethinylestradiol, had a rate of ALT elevation similar to those not receiving any oestrogens; however, due to the limited number of women taking these other oestrogens, caution is warranted for co-administration with the combination therapeutic regimen ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin and also the regimen with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir/voxilaprevir (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) ribavirin (HOS-088127) dasabuvir (HOS-110302) voxilaprevir (HOS-108930) ombitasvir (HOS-110300) velpatasvir (HOS-108929) ritonavir (HOS-084521) paritaprevir (HOS-110301)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-10T12:55:00Z · SHA-256 69e66a6243c1d9a3de0a88ac010cbabd1405527c8e76c9065b3d238f26ce840f · Passage c92123817fa43e381ccd32c0c58e6b45274765dc7c131039359791d0adbbf99d · Zeichen 4095–4862 im Abschnitt